Note: The Gilead HIV Cure Mentored Scientist award is currently being offered during the Fall 2023 RAP Cycle, deadline October 2, 2023.
The purpose of the Gilead HIV Cure Mentored Scientist Award at the amfAR Institute for HIV Cure Research is to mentor and train early stage investigators participating in HIV cure research. The award is open to investigators at a senior stage of clinical or postdoctoral training, and to new faculty at UCSF and affiliated partner institutes. Cure research projects can be in behavioral, clinical or basic laboratory science. Applications including research participants from underserved populations or from investigators underrepresented in HIV cure science are particularly encouraged. Applicants for this award must indicate a faculty research mentor(s) who will commit to guiding the applicant throughout the duration of the proposed project. Funded through the ARI, the application is processed through the UCSF Resource Allocation Program (RAP).
The award amount for this program is $45,000 in direct costs for one year.
For more information, please see the RAP portal.
Spring 2023 Awardee
Development and delivery of next-generation epigenome editors for long-term HIV silencing
Spring 2022 Awardee
Deep phenotyping of NK cells from HIV+ individuals undergoing antiretroviral treatment interruption
Spring 2020 Awardee
Improving efficacies of latency reversing agents by increasing CycT1 proteins in latently infected cells
Fall 2019 Awardees
Defining sirolimus dosing targets for HIV cure
Zain Dossani, PhD
Deciphering the regulation of CD8+ T cell hyporesponsiveness in HIV infection by interrogating chromatin accessibility at the single-cell level
Spring 2019 Awardee
A comprehensive immunologic analysis of HIV ‘extraordinary’ controllers as a model for durable HIV suppression
Spring 2018 Awardees
Exploring the role of TCF-7 in the regulation of HIV-specific CD8+ T Cell
Targeting SMYD5 Mediated Tat Methylation to Silence Latent HIV-1
Spring 2017 Awardees
Replenishment of the HIV reservoir following reactivation of latent HIV
Identifying potent, non-toxic latency reversing agents that function through the mTOR pathway